Promising prostate cancer drug extended to patients already improving
NCT ID NCT04145375
First seen May 09, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694 if they are already benefiting from it in an earlier trial. About 40 participants will receive the drug for up to two more weeks after their previous treatment ends. The main goal is to track side effects, while also measuring tumor response and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
University of California San Francisco Medical Center
San Francisco, California, 94104, United States
Conditions
Explore the condition pages connected to this study.